Trials / Completed
CompletedNCT04911751
A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- KoBioLabs · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to investigate efficacy and safety of KBL697 in patients with Moderate Plaque Type Psoriasis. KBL697 has been developed as a potential new treatment for Psoriatic Plaque.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KBL697 | 1 capsule BID of KBL697 or Placebo |
| DRUG | KBL697 | 5 capsules BID of KBL697 or Placebo |
Timeline
- Start date
- 2021-11-08
- Primary completion
- 2023-11-08
- Completion
- 2024-10-07
- First posted
- 2021-06-03
- Last updated
- 2025-01-07
Locations
10 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04911751. Inclusion in this directory is not an endorsement.